See the source article by following the link below:
A single administration of CRISPR/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing in mouse livers. Highlights the potential of this system to potentially treat human liver diseases, such as TTR amyloidosis or hepatitis B infection.
A single administration of CRISPR/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing in mouse livers. Highlights the potential of this system to potentially treat human liver diseases, such as TTR amyloidosis or hepatitis B infection.
No comments:
Post a Comment